) recently announced that it received CE Mark in Europe for
its drug eluting stent - Xience Xpedition 48 Everolimus Eluting
Coronary Stent System.
Xience Xpedition 48 is the latest addition to Abbott Labs'
Xience drug-eluting stent franchise. The product is designed to
enable treatment for very long blockages in the vessels that
supply blood to the heart due to coronary artery disease
The Xience drug-eluting stent family is a core part of Abbott
Labs' vascular business. We note that Abbott Labs has been
consistently making efforts to innovate its Xience drug-eluting
stent franchise (includes Xience V, Prime, nano and Xpedition)
over the last three years.
Xience nano and Xience Prime were launched in the US in 2011
while Xience Prime and Xience V were launched in Japan in Apr
2012 and Jan 2010, respectively. The launch of Xience Xpedition
in the US in Jan 2013 further boosted the franchise. Moreover,
Abbott Labs expects Xience Xpedition to gain approval in Japan by
The continued uptake of Xience Xpedition in the US along with
the expected launch of Xience Xpedition in Japan coupled with
other products should drive growth in the vascular business in
the second quarter of 2013.
Following the separation of its research-based pharmaceuticals
business into a new company,
), in Jan 2013, Abbott Labs became a diversified medical products
company with focus on branded generic pharmaceutical, medical
devices, diagnostic and nutritional businesses.
We believe the diversification bodes well for Abbott Labs and
should enable the company to counter the challenging business
environment in 2013 as a result of austerity measures undertaken
by developed markets in 2013 coupled with weak economic
conditionsand a mixed global economy.
Abbott Labs currently carries a Zacks Rank #3 (Hold).
) look well placed with a Zacks Rank #2 (Buy).
ABBVIE INC (ABBV): Free Stock Analysis Report
ABBOTT LABS (ABT): Free Stock Analysis Report
ATRICURE INC (ATRC): Free Stock Analysis
TRANS1 INC (TSON): Free Stock Analysis Report
To read this article on Zacks.com click here.